Mesoblast Ltd
Save
966.28M
Market cap
–
Current P/E
769.23x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Similar securities
Based on sector and market capitalization
Report issue